Abstract:
The comparative efficiency of long term use of fenspirid and atrovent in 42 patients with chronic obstructive pulmonary disease was studied. It was noted that the 6 months administration of fenspirid contributed to a 2,6 times cough intensity decrease and atrovent – a 1,2 time decrease. The anti-inflammatory therapy had a positive effect on the level of proinflammatory cytokines that registered a 3 times decrease in patients that used fenspirid and 1,5 time decrease after atrovent. During the long term treatment with fenspirid VEF1 increased by 35,5% and by 21,2% - during the basic therapy.
La 42 bolnavi cu bronhopneumapatie cronică obstructivă a fost studiată eficacitatea comparativă a tratamentului de durată cu fenspirid şi Atrovent. A fost stabilit că administrarea fenspiridului timp de 6 luni duce la micşorarea tusei de 2,6 ori, iar Atrovent – de 1,2 ori. Terapia antiinflamatorie a avut efect asupra citokinelor proinflamatoare, care s-au micşorat pe fon de tratament cu fenspirid de 3 ori, iar cu Atrovent de 1,5 ori. În rezultatul tratamentului de durată cu fenspirid VEMS a crescut cu 35,5%, iar pe fon de tratament de bază numai cu 21,2%.
